Corporate Dealers in Sheep’s Clothing
Sativex was the first modern Sheepshield — a corporate tincture disguised as innovation. Now that tinctures are legal and the acidic‑cannabinoid patent has expired, the wolf behind the wool is finally visible.
Tag Legalisation
Examining pathways to cannabis legalisation, including descheduling, regulatory models, political incentives, and the structural reforms needed for a functional post‑prohibition system.
Patented vs Herbal Pathway in a Rescheduled Era
The move to Schedule III didn’t settle the argument over Cannabis medicine — it spotlighted it. Two pathways still define the future: patented pharmaceuticals or the herbal gold standard. A dual‑track system where one pathway is federally empowered, while the other remains structurally constrained.
Treaty Troubles Ahead with US Crackdown on Hemp
The U.S. hemp crackdown isn't just American news—it's a treaty-powered warning to the world. By realigning with the 1961 UN Single Convention, the U.S. is demonstrating how international law can be used to erase a multi-billion dollar industry overnight. This move threatens the foundation of global cannabis reform. For Australia, the path forward is clear: we must build a smarter, sovereign regulatory model or risk having our progress dictated by outdated global prohibition.
Crystal Ball Predictions with Bill & Emjay
Crystal Ball Predictions with Bill & Emjay cuts through the smoke and mirrors to reveal how the 2026 patent expiry, Schedule III reform, and shifting market forces are about to reshape cannabinoid medicine. Follow the money, see the signals, and watch the future unfold.
Cannabis Policy Follows The Money
Public trust in leadership is declining globally. Awareness of corporate concentration, lobbying power, and regulatory capture is rising. Cannabis policy sits at the intersection of all three. This is no longer simply a debate about health or legality; it has become a broader issue.
Decriminalisation vs Legalisation: Who Gets Your Money?
Cannabis decriminalisation reduces harm to individuals, but it does not change the system that supplies the product. When possession becomes safer, but supply remains illegal, the illicit market continues to thrive. Legalisation, by contrast, replaces criminal distribution with a regulated market that improves safety, reduces enforcement costs, and redirects public funds.
The Dream of Free Weed vs. The Nightmare of Reality
Advocates imagine Cannabis treated like wine — safe, regulated, and accessible. But outdated treaties, corporate lobbying, and judicial conservatism keep reform trapped in legal limbo.
The Slippery Slope of Hemp Legislation
THC limits in hemp don’t just affect farmers — they shape global energy, agriculture, and bio-diesel futures. Can rational regulation unlock hemp’s full potential?
Medican: Your health is our business
In Australia, Cannabis for medical purposes is legal but tightly regulated. Patients cannot grow their own supply, and prices remain high due to licensing and pharmaceutical distribution.
Fit‑for‑Duty Workplace Drug Testing
Current workplace drug testing laws punish workers for lawful off‑duty Cannabis use by measuring presence, not impairment. This article explains why impairment‑based testing better protects safety, how enterprise agreements can embed fairer standards, and why the Cannabis Workers Union of Australia is proposed as a rallying point for reform.